I am a
Home I AM A Search Login

Papers of the Week

2017 Nov

Ann Oncol



Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.


Collins M, Michot JM, Danlos FX, Mussini C, Soularue E, Mateus C, Loirat D, Buisson A, Rosa I, Lambotte O, Laghouati S, Chaput N, Coutzac C, Voisin AL, Soria JC, Marabelle A, Champiat S, Robert C, Carbonnel F
Ann Oncol. 2017 Nov; 28(11):2860-2865.
PMID: 32014221.


Immune check-point blockade agents have shown clinical activity in cancer patients but are associated with immune-related adverse events that could limit their development. The aim of this study was to describe the gastrointestinal immune-related adverse events (GI-irAE) in patients with cancer treated with anti-PD-1.